Last reviewed · How we verify

Pyrimethamine (PYR) — Competitive Intelligence Brief

Pyrimethamine (PYR) (Pyrimethamine (PYR)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimalarial and antiparasitic agent. Area: Infectious Disease.

marketed Antifolate antimalarial and antiparasitic agent Dihydrofolate reductase (DHFR) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Pyrimethamine (PYR) (Pyrimethamine (PYR)) — Erasmus Medical Center. Pyrimethamine inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and thereby preventing DNA synthesis in parasites and certain microorganisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pyrimethamine (PYR) TARGET Pyrimethamine (PYR) Erasmus Medical Center marketed Antifolate antimalarial and antiparasitic agent Dihydrofolate reductase (DHFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimalarial and antiparasitic agent class)

  1. Erasmus Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pyrimethamine (PYR) — Competitive Intelligence Brief. https://druglandscape.com/ci/pyrimethamine-pyr. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: